Fatal lung metastasis secondary to index finger giant cell tumor in an 8-year-old child

Jacopin, S.; Viehweger, Elke; Glard, Yann; Launay, Franck; Jouve, Jean-Luc; Bouvier, Corinne; Bollini, G.

doi:10.1016/j.otsr.2009.12.007

Cited by 21 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interval from the time of surgery on the primary lesion to the occurrence of pulmonary metastasis can be as little as several months or more than 10 years. However, in most cases metastases were found within three years after the surgical treatment of the initial lesion [30, 31]. Based on the current literature (Table 1), approximately 3% of GCTB metastasizes to lung at certain time points after the confirmed diagnosis of primary GCTB.…”

Section: Pulmonary Metastasis Of Giant Cell Tumor Of Bonementioning

confidence: 99%

Pulmonary metastasis of giant cell tumor of bones

Muheremu

Niu

2014

World J Surg Onc

View full text Add to dashboard Cite

Giant cell tumor of bone (GCTB) accounts for 5% of primary skeletal tumors. Although it is considered to be a benign lesion, there are still incidences of pulmonary metastasis. Pulmonary metastasis of GCTB may be affected by tumor grading and localization as well as the age, gender and overall health status of the patient. Patients with local recurrence are more likely to develop pulmonary metastasis of GCTB. High expression of some genes, cytokines and chemokines may also be closely related to the metastatic potential and prognosis of GCTB. The treatment of the primary GCTB is key to the final outcome of the disease, as intralesional curettage has a significantly higher local recurrence and pulmonary metastasis rate than wide resection. However, even patients with pulmonary metastasis seem to have a good prognosis after timely and appropriate surgical resection. It is hoped that with the development of novel surgical methods and drugs, pulmonary metastasis of GCTB can be prevented and treated more effectively.

show abstract

Section: Pulmonary Metastasis Of Giant Cell Tumor Of Bonementioning

confidence: 99%

Pulmonary metastasis of giant cell tumor of bones

Muheremu

Niu

2014

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Although there is no large well‐controlled study on the long‐term outcomes of skeletally immature giant cell tumors and according to the small series of 10 patients by Fain et al., their behavior is similar to that of the typical epiphyseal giant cell tumor, with a recurrence rate of 43% after curettage , occasional cases of giant cell tumor in skeletally immature patient with aggressive course and fatal outcome have been reported . Metaphyseal giant cell tumor in the skeletally immature thus merits careful investigation and close follow‐up.…”

Section: Discussionmentioning

confidence: 99%

Fibular giant cell-rich osteosarcoma virtually indistinguishable radiographically and histopathologically from giant cell tumor-analysis of subtle differentiating features

Chow

2015

APMIS

View full text Add to dashboard Cite

Giant cell-rich osteosarcoma by its abundance of osteoclastic giant cells and paucity of tumor osteoid, leads to its easy confusion with giant cell tumor during biopsy interpretation. In this report, we describe a unique case of upper fibular metaphyseal giant cell-rich osteosarcoma in a 12-year-old boy; the radiographic and histopathologic features of the biopsy and initial resected tumor are virtually indistinguishable from conventional giant cell tumor. The tumor rapidly recurred 7 months after resection with metastasis to the groin lymph nodes, was resistant to first-line chemotherapy and pursued an aggressive course, developing disseminated metastasis to the lung, liver, pelvis, scapula and clavicle, and resulted in the death of the patient 21 months after initial presentation. The subtle features alerting one to the possibility of giant cell-rich osteosarcoma are retrospectively evaluated in comparison with cases of metaphyseal conventional giant cell tumors, four from our records and those from literature review. We conclude that the occurrence of a giant cell-rich lesion in the metaphysis of a skeletally immature individual merits careful assessment for the presence of periosteal reaction, permeative infiltrative margins, lacelike osteoid formation, high mitotic activity or Ki67 proliferative index, and extra-tumoral lymphovascular permeation, since the possibility of an aggressive lesion notably giant cell-rich osteosarcoma probably increases with the number of such features.

show abstract

“…1,3,5 Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens and interferon a-2b. For this reason, many authors consider its prognosis unpredictable.…”

Section: Discussionmentioning

confidence: 99%

“…It is usually a benign tumor but may present with high local aggressiveness, even with a risk for metastatic diseases, primarily to the lungs. [1][2][3][4][5][6] The pathophysiological studies of GCTB show high concentrations of RANK ligand (RANKL) in the neoplastic stromal cells. Most local recurrences occur within the first 2 years after diagnosis.…”

mentioning

confidence: 99%

Golden Bullet—Denosumab

Demırsoy

Karadoğan

Selek

et al. 2014

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB.

show abstract

Fatal lung metastasis secondary to index finger giant cell tumor in an 8-year-old child

Cited by 21 publications

References 13 publications

Pulmonary metastasis of giant cell tumor of bones

Pulmonary metastasis of giant cell tumor of bones

Fibular giant cell-rich osteosarcoma virtually indistinguishable radiographically and histopathologically from giant cell tumor-analysis of subtle differentiating features

Golden Bullet—Denosumab

Contact Info

Product

Resources

About